Sitagliptin: study card

Sitagliptin — DPP-4 inhibitor (gliptin). Study the mechanism, listed uses and warnings from the US label on one sourced card.

Generic name
Sitagliptin
Class
DPP-4 inhibitor (gliptin)
Mechanism
A DPP-4 inhibitor believed to act by slowing incretin inactivation. It increases and prolongs active GLP-1 and GIP levels, which influence insulin and glucagon in a glucose-dependent manner.
Used for
Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes
Common side effects
Upper respiratory tract infection; Nasopharyngitis; Headache
Warnings
Pancreatitis; Heart failure; Acute renal failure
Interactions
Insulin or insulin secretagogues (sulfonylureas)

Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.

Drug class families: DPP-4 inhibitors

Read the source label ↗

Label date: 20260812 · For learning, not clinical decisions. US label and brand information; always consult the current source.

Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.

Pronunciation

Sitagliptin: sit-a-GLIP-tin

Shared name ending: -gliptin · Linagliptin

Pronunciation is shown for the US English generic name. A name ending is a memory cue, not a classification rule.

Other drugs in the same class

DPP-4 inhibitors: Linagliptin

Body system

Endocrine · 27 Drug cards

Compare with related cards

Linagliptin

Same class family: DPP-4 inhibitors

Mechanism: Inhibits DPP-4, raising active GLP-1 and GIP; increases glucose-dependent insulin release and lowers glucagon.

On both cards: Common side effects — Nasopharyngitis · Warnings — Pancreatitis

Only on the Linagliptin card: Used for — Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes · Common side effects — Hypoglycemia with insulin or secretagogues · Warnings — Severe, disabling arthralgia; Bullous pemphigoid · Interactions — Strong P-gp/CYP3A4 inducers (e.g., rifampin); Insulin and insulin secretagogues

Pioglitazone

Same body system: Endocrine

Mechanism: PPAR-gamma agonist that decreases insulin resistance in periphery and liver; requires insulin, not a secretagogue.

On both cards: Common side effects — Upper respiratory tract infection; Headache

Only on the Pioglitazone card: Used for — Type 2 diabetes in adults, as an adjunct to diet and exercise · Common side effects — Sinusitis; Myalgia; Pharyngitis · Warnings — Hepatic failure (postmarketing); Bladder cancer; Edema and fractures · Interactions — Strong CYP2C8 inhibitors (e.g., gemfibrozil); CYP2C8 inducers (e.g., rifampin); Topiramate

An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.